KPTI Q2 2025: Sentry Trial Nears Completion, $1B Myelofibrosis Opportunity Takes Shape
CurioFarm Therapeutics (KPTI) enters a pivotal phase, closing screening for its Sentry phase 3 myelofibrosis trial and preparing for up to three major data readouts in 2026. The company’s commercial multiple myeloma franchise remains stable, while cost discipline and workforce reductions are being deployed to address a looming debt maturity. Investor focus now shifts to the durability of Selenexor’s clinical profile and management’s ability to navigate near-term liquidity risks as transformative opportunities approach.
Summary
- Sentry Milestone: Phase 3 myelofibrosis trial enrollment closes, setting up a high-stakes 2026 readout.
- Liquidity Crunch: Debt maturity in October drives urgency for financing or strategic alternatives.
- Commercial Foundation: Multiple myeloma sales and global royalties provide a base for pipeline expansion.
Performance Analysis
CurioFarm’s commercial engine in multiple myeloma, anchored by Expovio, continues to deliver steady product revenue, with the community setting accounting for about 60% of U.S. sales. Net product revenue for Expovio grew 6% year over year, reflecting consistent demand and normalization of product returns after an atypical Q1. Royalty revenue from international partners jumped 28%, signaling incremental global traction for Selenexor-based therapies.
However, total revenue declined versus the prior year due to the absence of one-time license-related revenue, and the company remains unprofitable on a GAAP basis. Operating losses were driven by ongoing R&D investment, though cost control efforts—including a 20% workforce reduction—are expected to yield $13 million in annualized savings from 2026. Liquidity remains the central concern, with $52 million in cash and equivalents and a senior note maturity looming in October. Management is actively pursuing financing and strategic alternatives to extend runway beyond early 2026.
- R&D Spend Rationalization: Down 15% YoY, driven by headcount cuts and trial cost optimization.
- SG&A Discipline: Down 8% YoY as cost initiatives take hold, with further impact expected in Q4 and beyond.
- Gross-to-Net Improvement: Provisions normalized to 26.8% from an elevated Q1, supporting margin stability.
Overall, the core business is stable but not self-sustaining, placing extraordinary pressure on upcoming clinical milestones and capital actions to define KPTI’s trajectory into 2026.
Executive Commentary
"We are operating in a period of financial constraints, with a near-term debt maturity in October. We are actively engaged with our lenders and advisors to enhance our liquidity and maximize value. Importantly, the fundamentals of our business remain strong with a profitable multi-myeloma commercial organization that provides us with a solid foundation that we can build on with two potentially transformative phase three readouts expected over the next 12 months."
Richard Polson, President and Chief Executive Officer
"We continue to be very diligent in allocating our resources and pipeline prioritization. We announced a roughly 20% reduction in our workforce in early July. You will start to see the financial impact of these actions when we report our results for the fourth quarter of this year."
Lori, Chief Financial Officer
Strategic Positioning
1. Myelofibrosis: Sentry Trial as Value Catalyst
The Sentry phase 3 trial in JAK-naive myelofibrosis is the company’s near-term inflection point, with patient screening closing and topline data expected in March 2026. Selenexor, an XPO1 inhibitor, is being positioned as the first combination regimen with ruxolitinib, aiming to address the limitations of JAK inhibitors alone. Early blinded safety data suggest the combination may offer a comparable or improved tolerability profile, particularly with lower rates of grade 3-4 anemia and discontinuations. If successful, management estimates U.S. peak annual revenue potential at $1 billion, with rapid commercial uptake anticipated due to strong physician interest and existing prescriber overlap.
2. Pipeline Breadth and Readout Clustering
Three pivotal trial readouts are expected in 2026: myelofibrosis (Sentry), endometrial cancer (EXPORT ECO42), and multiple myeloma (EMN29 SPD). The organization is leveraging its commercial infrastructure and prescriber overlap to prepare for simultaneous launches, should data be positive. This clustering amplifies both upside and operational risk, as execution bandwidth and market access must scale quickly if multiple programs succeed.
3. Commercial and Global Expansion
Expovio continues to anchor the business in multiple myeloma, with community-based oncologists driving the majority of sales. The company is expanding global patient access, now with approvals in 50 countries and increasing royalty streams. Management is leveraging existing relationships for potential rapid uptake in new indications, minimizing incremental commercial investment for myelofibrosis and endometrial cancer launches.
4. Cost Structure and Resource Allocation
Cost discipline is now central, with R&D and SG&A both trending down due to headcount and contractor reductions. These moves are designed to preserve liquidity and focus resources on late-stage clinical programs. However, the company’s ability to invest in launch readiness and pipeline breadth will remain constrained until new capital is secured or debt is refinanced.
5. Regulatory and Clinical Execution
Trial design optimization and regulatory alignment have been a focus, with primary endpoints in Sentry adjusted for sensitivity and FDA feedback. The use of dual antiemetics and endpoint selection (absolute TSS, excluding fatigue) reflect learnings from prior studies and evolving regulatory expectations. Continued engagement with FDA is seen as a positive, but management acknowledges the need for robust data to secure approval and commercial success.
Key Considerations
KPTI’s Q2 was defined by operational discipline, clinical execution, and balance sheet urgency. The next year will test the company’s ability to convert clinical promise into commercial reality while navigating acute liquidity constraints.
Key Considerations:
- Debt Maturity Overhang: October 2025 note maturity forces near-term resolution on financing or strategic alternatives.
- Clinical Readout Risk: Sentry topline data in myelofibrosis is binary for valuation and future funding access.
- Commercial Leverage: Physician overlap between myelofibrosis, myeloma, and endometrial cancer offers launch synergies but also execution complexity.
- Cost Rationalization: Workforce reduction and spend cuts may limit flexibility if multiple launches are required in close succession.
- Regulatory Alignment: Endpoint changes and antiemetic protocols aim to maximize approvability and real-world adoption.
Risks
KPTI faces acute liquidity risk, with cash projected to last only into early 2026 absent new financing or a strategic transaction. The outcome of the Sentry trial is pivotal; negative or equivocal results would undermine both funding prospects and long-term viability. Operational risk is elevated as the company prepares for up to three major launches, each requiring flawless execution and regulatory navigation. Competitive dynamics in both myelofibrosis and multiple myeloma remain intense, and reimbursement headwinds or slower-than-expected uptake could further pressure the business.
Forward Outlook
For Q3 2025, CurioFarm guided to:
- Total revenue of $140 to $155 million for full-year 2025
- U.S. Expovio net product revenue of $110 to $120 million
For full-year 2025, management maintained guidance:
- R&D and SG&A expenses of $240 to $250 million
Management emphasized that existing liquidity is sufficient only through the October debt maturity, and that all options—including financing and strategic alternatives—are being explored with advisors. Investors should expect heightened volatility around upcoming clinical data and capital market developments.
- Debt resolution and cash runway are critical watchpoints
- Clinical trial milestones in 2026 will shape strategic direction
Takeaways
KPTI’s investment case is now a high-conviction bet on late-stage clinical outcomes and capital market access. The company’s commercial base in multiple myeloma offers stability, but cannot offset the urgency of the October debt wall or the binary risk of the Sentry trial. Management’s cost discipline and operational focus are positives, but success depends on flawless execution and positive data.
- Binary Catalyst Looms: The Sentry phase 3 readout in myelofibrosis is the make-or-break event for the company.
- Liquidity Dictates Strategy: Near-term debt forces capital action, with strategic alternatives on the table.
- Operational Readiness Will Be Tested: Multiple launches could strain resources if data across programs are positive.
Conclusion
CurioFarm Therapeutics is entering a decisive period, with transformative clinical catalysts and an urgent need to resolve liquidity. The company’s foundation in multiple myeloma and global expansion provide a commercial base, but the next year will be defined by the Sentry trial outcome and management’s ability to secure new capital. Investors should monitor both clinical and capital market developments closely.
Industry Read-Through
KPTI’s experience highlights the increasing importance of combination therapies and biomarker-driven development in hematologic malignancies, as well as the operational and financial strain of running multiple late-stage programs in parallel. Liquidity risk is front and center for small and mid-cap biotech, particularly those with major readouts clustered around debt maturities. The company’s approach to commercial leverage—using existing field infrastructure and prescriber overlap—may become a model for others seeking to optimize launch costs across adjacent indications. The sector will be watching closely for signals on regulatory pathways, trial design sensitivity, and the real-world adoption curve for new combination regimens.